Synapse Open Synapse
Biology

Disc’s once-spurned rare disease drug to get a second chance at approval

BioPharma Dive · · 3 min read

Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.

Latest from BioPharma Dive